213250-58-9

Basic information

• Product Name: Cyclohexanecarboxylic acid, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-oxo-, methyl ester, (3R,5R)-
• CAS NO: 213250-58-9
• Molecular Formula: C20H40O6Si2
• Molecular Weight: 432.705
• Mol File: 213250-58-9.mol
• Article Data: 25

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarboxylic acid, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-oxo-, methyl ester, (3R,5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-oxo-, methyl ester, (3R,5R)-(213250-58-9)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-oxo-, methyl ester, (3R,5R)-(213250-58-9)

Safety Data

• Hazardous Substances Data: 213250-58-9(Hazardous Substances Data)

Upstream product

• 191916-39-9 methyl (-)-quinate 
• 77-95-2 D-(-)-quinic acid 
• 141404-07-1 (3R,5R)-3,5-bis[tert-butyl(dimethyl)silyloxy]-1-(hydroxymethyl)-1,4-cyclohexanediol 
• 135711-62-5 methyl quinicate 

Downstream Products

• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 
• 77-95-2 D-(-)-quinic acid 
• 35949-53-2 (-)-4,5-cyclohexylidenequinic acid lactone 
• 193956-42-2 meso-methyl 5-epi-quinate 
• 135558-85-9 cis-quinic acid 
• 50459-25-1 (-)-methyl 4-epi-quinate 
• 77-95-2 (1R,3R,4R,5R)-(-)-quinic acid 
• 99-94-5 p-Toluic acid 
• 852658-76-5 C₃₆H₆₆O₂Si₂ 
• 852658-61-8 C₃₄H₆₂O₂Si₂ 
• 852658-66-3 C₃₅H₆₄O₂Si₂ 
• 852658-46-9 2-Methylene-(20S)-19-nor-1alpha-hydroxy-trishomopregnacalciferol 
• 852658-44-7 (20R)-1alpha-Hydroxy-2-methylene-19-nor-bishomopregnacalciferol 
• 852658-50-5 2-methylene-19,21-dinor-1α-hydroxybishomopregnacalciferol 

Relevant articles and documents

P-TOLUIC ACID PRODUCING METHOD

A method for producing highly pure p-toluic acid by a simple solid-liquid separation operation using as a raw material a substance inducible from a biomass resource and suitable for fermentation production by a microorganism is disclosed. The method for producing p-toluic acid includes: a dehydration reaction step of dehydrating Compound(s) (1)-(4), which are substances inducible from biomass resources and suitable for fermentation production by microorganisms; and a solid-liquid separation step of recovering a solid produced by this dehydration reaction by a simple solid-liquid separation operation.

Synthesis of 2-ethyl-19-nor analogs of 1α,25-dihydroxyvitamin D 3

The synthesis of two new A-ring precursors, useful for the convergent assembly of 2α-ethyl and 2β-ethyl derivatives of 19-nor-1α,25- dihydroxyvitamin D3, is described. These building blocks were prepared in 14 steps from quinic acid, which led to a new and practical synthesis of 2α-ethyl-14-epi-19-nor-20-epi-23-yne-1,25(OH) 2D3, an analog that shows a remarkably low calcemic effect in mice, while retaining the ability to promote cell differentiation and to inhibit cell proliferation in a number of human cancer cell lines. Two new phosphanone building blocks, useful for the stereocontrolled synthesis of 2-ethyl-substituted 19-nor analogs of 1α,25-dihydroxyvitamin D 3, were prepared from quinic acid. This route offers an attractive practical solution for the introduction of these synthetically challenging but highly interesting A-ring modifications. Copyright

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen, or a pharmaceutically acceptable salt